These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 32954860)

  • 21. What is needed for the roll-out of psychedelic treatments?
    Xenakis SN; Shannon SM
    Curr Opin Psychiatry; 2024 Jul; 37(4):277-281. PubMed ID: 38726805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethical considerations for psychedelic-assisted therapy in military clinical settings.
    Hoener S; Wolfgang A; Nissan D; Howe E
    J Med Ethics; 2024 Mar; 50(4):258-262. PubMed ID: 37253556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin and MDMA for the treatment of trauma-related psychopathology.
    Bird CIV; Modlin NL; Rucker JJH
    Int Rev Psychiatry; 2021 May; 33(3):229-249. PubMed ID: 34121583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
    Kisely S
    Aust N Z J Psychiatry; 2023 Jul; 57(7):933-934. PubMed ID: 37161273
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential Therapeutic Effects of Psilocybin.
    Johnson MW; Griffiths RR
    Neurotherapeutics; 2017 Jul; 14(3):734-740. PubMed ID: 28585222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
    Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
    Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.
    Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS
    Neuropharmacology; 2022 Aug; 214():109127. PubMed ID: 35577136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelic Psychiatry's Brave New World.
    Nutt D; Erritzoe D; Carhart-Harris R
    Cell; 2020 Apr; 181(1):24-28. PubMed ID: 32243793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
    Sarparast A; Thomas K; Malcolm B; Stauffer CS
    Psychopharmacology (Berl); 2022 Jun; 239(6):1945-1976. PubMed ID: 35253070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
    Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
    J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.